Novel anti-fibrotic engineered macrophage therapy reduced liver fibrosis in preclinical models Development candidate nomination expected in the first quarter of 2025 PHILADELPHIA, May 8, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced new data demonstrating preclinical proof of concept using engineered anti-fibrotic macrophages for the treat ...